Viewing data from:

CEFADROXIL

ANDA

CEFADROXIL/CEFADROXIL HEMIHYDRATE | A062291 | SANDOZ INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Cefadroxil (2023)

Total Spending

$6.4M

Total Claims

413,388

Beneficiaries

315,336

Avg Cost/Unit

$0.60

Spending Trend

$3.0M(2019)→$3.4M(2020)→$4.0M(2021)→$5.2M(2022)→$6.4M(2023)

YoY Change:+2.9%

5yr CAGR:+4.4%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — EQ 500MG BASE

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.